Rituximab: Expanding role in therapy for lymphomas and autoimmune diseases

Annual Review of Medicine

Volumn 55, Issue , 2004, Pages 477-503

  Rastetter, William ^a   Molina, Arturo ^a   White, Christine A ^a  

^a BIOGEN   (United States)

Author keywords

B cell depletion; CD20 antigen; Immunotherapy; Monoclonal antibody

Indexed keywords

ALEMTUZUMAB; ANTIHISTAMINIC AGENT; CYCLOPHOSPHAMIDE; DOXORUBICIN; EDRECOLOMAB; FLUDARABINE; IBRITUMOMAB TIUXETAN; PREDNISOLONE; RITUXIMAB; THALIDOMIDE; TRASTUZUMAB; VINCRISTINE;

ANTIBODY DEPENDENT LEUKOCYTE CYTOTOXICITY; ANTIBODY PRODUCTION; AUTOIMMUNE DISEASE; B CELL LYMPHOMA; CANCER IMMUNOTHERAPY; CELL DIFFERENTIATION; CHILL; CHROMOSOME REARRANGEMENT; CHROMOSOME TRANSLOCATION 4; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DNA MICROARRAY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; HUMAN; HYPOTENSION; LOW DRUG DOSE; MEDICAL ASSESSMENT; PLASMA CELL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; RANDOMIZED CONTROLLED TRIAL; RELAPSE; REVIEW; TREATMENT INDICATION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AUTOIMMUNE DISEASES; HUMANS; LYMPHOMA;

EID: 1542358942     PISSN: 00664219     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.med.55.091902.104249     Document Type: Review

References (144)

1. Grillo-Lopez AJ, Hedrick E, Rashford M, et al. 2002. Rituximab: ongoing and future clinical development. Semin. Oncol. 29:105-12
2. Davis TA, White CA, Grillo-Lopez AJ, et al. 1999. Single-agent monoclonal antibody efficacy in bulky non-Hodgkin's lymphoma: results of a phase II trial of rituximab. J. Clin. Oncol. 17:1851-57
3. Piro LD, White CA, Grillo-Lopez AJ, et al. 1999. Extended rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma. Ann. Oncol 10:655-61
4. Davis TA, Grillo-Lopez AJ, White CA, et al. 2000. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of retreatment. J. Clin. Oncol. 18:3135-43
5. Reff ME, Carner K, Chambers KS, et al. 1994. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 83:435-45
6. Valentine MA, Meier KE, Rossie S, et al. 1989. Phosphorylation of the CD20 phosphoprotein in resting B lymphocytes. Regulation by protein kinase C. J. Biol. Chem. 264:11282-87
7. Einfeld DA, Brown JP, Valentine MA, et al. 1988. Molecular cloning of the human B cell CD20 receptor predicts a hydrophobic protein with multiple transmembrane domains. EMBO J. 7:711-17
8. Anderson KC, Bates MP, Slaughenhoupt BL, et al. 1984. Expression of human B cell-associated antigens on leukemias and lymphomas: a model of human B cell differentiation. Blood 63:1424-33
9. Maloney DG, Grillo-Lopez AJ, White CA, et al. 1997. IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 90:2188-95
10. Shan D, Ledbetter JA, Press OW. 2000. Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells. Cancer Immunol. Immunother. 48:673-83
11. Taji H, Kagami Y, Okada K, et al. 1998. Growth inhibition of CD20-positive B lymphoma cell lines by IDEC-C2B8 anti-CD20 monoclonal antibody. Jpn. J. Cancer Res. 89:748-56
12. Flieger D, Renoth S, Beier I, et al. 2000. Mechanism of cytotoxicity induced by chimeric mouse human monoclonal antibody IDEC-C2B8 in CD20-expressing lymphoma cell lines. Cell. Immunol. 204:55-63
13. Pedersen IM, Buhl AM, Klausen P, et al. 2002. The chimeric anti-CD20 antibody rituximab induces apoptosis in B-cell chronic lymphocytic leukemia cells through a p38 mitogen activated protein-kinase-dependent mechanism. Blood 99:1314-19
14. Byrd JC, Kitada S, Flinn IW, et al. 2002. The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction. Blood 99:1038-43
15. Clynes RA, Towers TL, Presta LG, et al. 2000. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat. Med. 6:443-46
16. Cartron G, Dacheux L, Salles G, et al. 2002. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 99:754-58
17. Weng W-K, Levy R. 2002. Analysis of IgG Fc receptor FcgRIIIa polymorphism in relapsed follicular non-Hodgkin's lymphoma patients treated with rituximab. Blood 100(11):353a (Abstr.)
18. Treon SP, Fox EA, Hansen M, et al. 2002. Polymorphisms in Fc gamma RIIIa (CD16) receptor expression are associated with clinical response to rituximab in Waldenstrom's macroglobulinemia. Blood 100(11):573a (Abstr.)
19. Anolik JH, Campbell D, Felgar RE, et al. 2003. The relationship of FcgammaRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus. Arthritis Rheum. 48:455-59
20. Demidem A, Lam T, Alas S, et al. 1997. Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs. Cancer Biother. Radiopharm. 12:177-85
21. Alas S, Emmanouilides C, Hanna N, et al. 2000. Rituximab-mediated growth regulation and drug sensitization of B lymphoma: pivotal role of IL-10. Proc. Am. Assoc. Cancer Res. 41:288 (Abstr.)
22. Alas S, Emmanouilides C, Bonavida B. 2001. Inhibition of interleukin 10 by rituximab results in down-regulation of bcl-2 and sensitization of B-cell non-Hodgkin's lymphoma to apoptosis. Clin. Cancer. Res. 7:709-23
23. Vega MI, Huerta S, Garban H, et al. 2002. Involvement of the p38MAPK pathway in the inhibition of IL-10 synthesis and secretion by rituximab in 2F7 NHL cells: role in inhibition of bcl-2 expression and sensitization to chemotherapeutic drugs. Blood 100(11):572a-73a (Abstr.)
24. Rose AL, Smith BE, Maloney DG. 2002. Glucocorticoids and rituximab in vitro: synergistic direct antiproliferative and apoptotic effects. Blood 100:1765-73
25. Maloney DG, Smith B, Rose A. 2002. Rituximab: mechanism of action and resistance. Semin. Oncol. 29:2-9
26. Bohen SP, Troyanskaya OG, Alter O, et al. 2003. Variation in gene expression patterns in follicular lymphoma and the response to rituximab. Proc. Natl. Acad. Sci. USA 100:1926-30
27. Treon SP, Emmanouilides CE, Kimby E, et al. 2002. Extended rituximab therapy is highly effective and facilitates hematological recovery in patients with lymphoplasmacytic lymphoma (Waldenstrom's macroglobulinemia, WM). Proc. Am. Soc. Clin. Oncol. 21:268a (Abstr.)
28. Colombat P, Salles G, Brousse N, et al. 2001. Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation. Blood 97:101-6
29. Solal-Celigny P. 2002. Increasing treatment options in indolent non-Hodgkin's lymphoma. Semin. Oncol. 29:2-6
30. Witzig TE, Vukov AM, Habermann TM, et al. 2002. Rituximab therapy for patients with newly diagnosed, asymptomatic advanced-stage follicular grade I non-Hodgkin's lymphoma (NHL): a phase II trial in the North Central Cancer Treatment Group (NCCTG). Blood 100(11):361a (Abstr.)
31. Dimopoulos MA, Zervas C, Zomas A, et al. 2002. Treatment of Waldenstrom's macroglobulinemia with rituximab. J. Clin. Oncol. 20:2327-33
32. Conconi A, Thiéblemont C, Martinelli G, et al. 2001. Activity of rituximab in extranodal marginal zone lymphomas (MALT-type). Blood 98(11):807a (Abstr.)
33. O'Brien SM, Kantarjian H, Thomas DA, et al. 2001. Rituximab dose-escalation trial in chronic lymphocytic leukemia. J. Clin. Oncol. 19:2165-70
34. Byrd JC, Murphy T, Howard RS, et al. 2001. Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. J. Clin. Oncol. 19:2153-64
35. Hainsworth JD, Litchy S, Burris HA, 3rd, et al. 2002. Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma. J. Clin. Oncol. 20:4261-67
36. Foran JM, Cunningham D, Coiffier B, et al. 2000. Treatment of mantle-cell lymphoma with rituximab (chimeric monoclonal anti-CD20 antibody): analysis of factors associated with response. Ann. Oncol. 11:S117-S21
37. Foran JM, Rohatiner AZ, Cunningham D, et al. 2000. European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma. J. Clin. Oncol. 18: 317-24
38. Treon SP, Agus TB, Link B, et al. 2001. CD20-directed antibody-mediated immunotherapy induces responses and facilitates hematologic recovery in patients with Waldenstrom's macroglobulinemia. J. Immunother. 24:272-79
39. McLaughlin P, Grillo-Lopez AJ, Link BK, et al. 1998. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J. Clin. Oncol. 16:2825-33
40. McLaughlin P, Hagemeister FB, Grillo-Lopez AJ. 1999. Rituximab in indolent lymphoma: the single-agent pivotal trial. Semin. Oncol. 26:79-87
41. Cheson BD, Homing SJ, Coiffier B, et al. 1999. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. J. Clin. Oncol. 17:1244-53
42. Grillo-Lopez AJ, Cheson BD, Horning SJ, et al. 2000. Response criteria for NHL: importance of 'normal' lymph node size and correlations with response rates. Ann. Oncol. 11:399-408
43. Foran JM, Gupta RK, Cunningham D, et al. 2000. A UK multicentre phase II study of rituximab (chimaeric anti-CD20 monoclonal antibody) in patients with follicular lymphoma, with PCR monitoring of molecular response. Br. J. Haematol. 109:81-88
44. Walewski J, Kraszewska E, Mioduszewska O, et al. 2001. Rituximab (Mabthera, Rituxan) in patients with recurrent indolent lymphoma: evaluation of safety and efficacy in a multicenter study. Med.Oncol. 18:141-48
45. Igarashi T, Itoh K, Kobayashi Y, et al. 2002. Phase II and pharmacokinetic study of rituximab with eight weekly infusions in relapsed aggressive B-cell non-Hodgkin's lymphoma (B-NHL). Proc. Am. Soc. Clin. Oncol. 21(1):286a (Abstr.)
46. Coiffier B, Haioun C, Ketterer N, et al. 1998. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter Phase II study. Blood 92:1927-32
47. Coiffier B. 2002. Rituximab in the treatment of diffuse large B-cell lymphomas. Semin. Oncol. 29:30-35
48. Tsai DE, Moore HCF, Hardy CL, et al. 1999. Rituximab (anti-CD20 monoclonal antibody) therapy for progressive intermediate-grade non-Hodgkin's lymphoma after high-dose therapy and autologous peripheral stem cell transplantation. Bone Marrow Transplant. 24:521-26
49. Pan D, Moskowitz CH, Zelenetz AD, et al. 2002. Rituximab for aggressive non-Hodgkin's lymphomas relapsing after or refractory to autologous stem cell transplantation. Cancer J, 8:371-76
50. Ghielmini M, Hsu Schmitz S-F, Cogliatti S, et al. 2002. Prolonged treatment with rituximab significantly improves event free survival and duration of response in patients with follicular lymphoma: a randomised SAKK trial. Blood 100(11):161a (Abstr.)
51. Hainsworth JD. 2002. Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma: interim follow-up of a multicenter phase II trial. Semin. Oncol. 29:25-29
52. Berinstein NL, Grillo-Lopez AJ, White CA, et al. 1998. Association of serum rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma. Ann. Oncol. 9:995-1001
53. Huhn D, von Schilling C, Wilhelm M, et al. 2001. Rituximab therapy of patients with B-cell chronic lymphocytic leukemia. Blood 98:1326-31
54. Almasri NM, Duque RE, Iturraspe J, et al. 1992. Reduced expression of CD20 antigen as a characteristic marker for chronic lymphocytic leukemia. Am. J. Hematol. 40:259-63
55. 2001. Package insert. Rituxan® (rituximab), IDEC Pharmaceuticals Corporation, San Diego, CA
56. Coiffier B, Bouaffia F, Thieblemont C, et al. 2002. Rituximab re-treatment in B-cell lymphoma patients: efficacy and toxicity in 59 patients treated in one center. Blood 100(11):359a (Abstr.)
57. Coiffier B, Lepage E, Briere J, et al. 2002. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N. Engl. J. Med. 346:235-42
58. Vose JM, Link BK, Grossbard ML, et al. 2001. Phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma. J. Clin. Oncol. 19:389-97
59. Vose JM, Link BK, Grossbard ML, et al. 2002. Long-term follow-up of a phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated aggressive non-Hodgkin's lymphoma (NHL). Blood 100(11):361a (Abstr.)
60. Czuczman MS, Grillo-Lopez AJ, McLaughlin P, et al. 2001. Clearing of cells bearing the bcl-2 [t(14;18)] translocation from blood and marrow of patients treated with rituximab alone or in combination with CHOP chemotherapy. Ann. Oncol. 12:109-14
61. Hiddemann W, Unterhalt M, Dreyling M, et al. 2002. The addition of rituximab (R) to combination chemotherapy (CT) significantly improves the treatment of mantle cell lymphomas (MCL): results of two prospective randomized studies by the German Low Grade Lymphoma Study Group (GLSG). Blood 100(11):92a (Abstr.)
62. Howard OM, Gribben JG, Neuberg DS, et al. 2002. Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival. J. Clin. Oncol. 20:1288-94
63. Rodriguez MA, Sarris A, East K, et al. 2002. A phase II study of liposomal vincristine in CHOP with rituximab for patients with untreated aggressive B-cell non-Hodgkin's lymphoma (NHL): a safe and effective combination. Blood 100(11):92a (Abstr.)
64. Boue F, Gabarre J, Gisselbrecht C, et al. 2002. CHOP chemotherapy plus rituximab in HIV patients with high grade lymphoma - results of an ANRS trial. Blood 100(11):470a (Abstr.)
65. Wilson WH, Gutierrez M, O'Connor P, et al. 2002. The role of rituximab and chemotherapy in aggressive B-cell lymphoma: a preliminary report of dose-adjusted EPOCH-R. Semin. Oncol. 29:41-47
66. Martinelli G, Laszlo D, Mancuso P, et al. 2002. Rituximab plus chlorambucil in low-grade non Hodgkin's lymphomas (NHL): clinical results of a phase II study. Blood 100(11):777a (Abstr.)
67. Hainsworth JD, Burris HA, Yardley DA, et al. 2002. Rituximab plus short duration chemotherapy as first-line treatment for follicular non-Hodgkin's lymphoma (NHL): a Minnie Pearl Cancer Research Network phase II trial. Proc. Am. Soc. Clin. Oncol. 21(2):268a (Abstr.)
68. Maloney D, Press OW, Braziel RM, et al. 2001. A phase II trial of CHOP followed by rituximab chimeric monoclonal anti-CD20 antibody for treatment of newly diagnosed follicular non-Hodgkin's lymphoma: SWOG 9800. Blood 98(11):843a (Abstr.)
69. Rambaldi A, Lazzari M, Manzoni C, et al. 2002. Monitoring of minimal residual disease after CHOP and rituximab in previously untreated patients with follicular lymphoma. Blood 99:856-62
70. Czuczman MS, Fallon A, Mohr A, et al. 2002. Rituximab in combination with CHOP or fludarabine in low-grade lymphoma. Semin. Oncol. 29:36-40
71. Gregory SA, Venugopal P, Adler S, et al. 2002. Combined fludarabine, mitoxantrone, and rituximab achieves a high response as initial treatment for advances low grade non-Hodgkin's lymphoma (LGNHL). Blood 100(11):362a (Abstr.)
72. Zinzani PL. 2001. A randomized trial of fludarabine and mitoxantrone plus rituximab versus CHOP plus rituximab as first-line treatment in patients with follicular lymphoma. Blood 98(11):842a (Abstr.)
73. Zinzani PL. 2002. A multicenter randomized trial of fludarabine and mitoxantrone (FM) plus rituximab versus CHOP plus rituximab as first-line treatment in patients with follicular lymphoma (FL). Blood 100(11):93a (Abstr.)
74. Schulz H, Klein SK, Rehwald U, et al. 2002. Phase 2 study of a combined immunochemotherapy using rituximab and fludarabine in patients with chronic lymphocytic leukemia. Blood 100:3115-20
75. Keating M, Manshouri T, O'Brien S, et al. 2002. A high proportion of molecular remission can be obtained with a fludarabine, cyclophosphamide, rituximab combination (FCR) in chronic lymphocytic leukemia (CLL). Blood 100(11):205a (Abstr.)
76. Wierda W, O'Brien S, Albitar M, et al. 2001. Combined fludarabine, cyclophosphamide, and rituximab achieves a high complete remission as initial treatment of chronic lymphocytic leukemia. Blood 98(11):771a (Abstr.)
77. Sacchi S, Tucci A, Merli F, et al. 2002. Phase II study with fludarabine and cyclophosphamide plus rituximab (FC + R) in relapsed follicular lymphoma patients. Blood 100(11):572a (Abstr.)
78. Treon SP, Wasi P, Emmanouilides CA, et al. 2002. Combination therapy with rituximab and fludarabine is highly active in Waldenstrom's macroglobulinemia. Blood 100(11):211a (Abstr.)
79. Byrd JC, Peterson BL, Park K, et al. 2001. Concurrent rituximab and fludarabine has a higher complete response rate than sequential treatment in untreated chronic lymphocytic lymphoma (CLL) patients: results from CALGB 9712. Blood 98(11):772a (Abstr.)
80. Sarris AH, Jiang Y, Tsimberidou AM, et al. 2002. Quantitative real-time polymerase chain reaction for monitoring minimal residual disease in patients with advanced indolent lymphomas treated with rituximab, fludarabine, mitoxantrone, and dexamethasone. Semin. Oncol. 29:48-55
81. McLaughlin P, Hagemeister FB, Rodriguez MA, et al. 2000. Safety of fludarabine, mitoxantrone, and dexamethasone combined with rituximab in the treatment of stage IV indolent lymphoma. Semin. Oncol. 27:37-41
82. Schulz H, Rehwald U, Reiser M, et al. 2002. Phase-II trial of rituximab in patients with relapsed CD20-positive Hodgkin's lymphoma: an update from the German Hodgkin's Lymphoma Study Group (GHSG). Blood 100(11):775a (Abstr.)
83. Younes A, Fayad L, McLaughlin P, et al. 2002. Rituximab plus ABVD therapy for newly diagnosed patients with classical Hodgkin's disease. Blood 100(11):308b (Abstr.)
84. Ferry CK, Maillard A, Agbalika F, et al. 2002. Treatment of B-lymphoproliferative disorder after hematopoietic stem cell transplantation. Role and immunological follow-up of rituximab®. Blood 100(11):113a-14a (Abstr.)
85. Oertel SHK, Zeidler K, Grefer J, et al. 2002. Monotherapy with the anti-CD20 antibody rituximab (Ritux) in patients with post-transplant lymphoproliferative disease (PTLD): results of a multicentre phase II study. Blood 100(11):573a (Abstr.)
86. van Esser JW, Niesters HG, van der Holt B, et al. 2002. Prevention of Epstein-Barr virus-lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantation. Blood 99:4364-69
87. Milpied N, Vasseur B, Parquet N, et al. 2000. Humanized anti-CD20 monoclonal antibody (rituximab) in post transplant B-lymphoproliferative disorder: a retrospective analysis on 32 patients. Ann. Oncol. 11:s113-16
88. Choquet S, Herbrecht R, Socié G, et al. 2002. Efficacy and safety of rituximab in B-cell post transplantation lymphoproliferative disorders (B-PTLD): preliminary results of a multicenter, open label, phase II trial (M39037 TRIAL). Blood 100(11):467a (Abstr.)
89. Mangel J, Buckstein R, Imrie K, et al. 2002. Pharmacokinetic study of patients with follicular or mantle cell lymphoma treated with rituximab as "in vivo purge" and consolidative immunotherapy following autologous stem cell transplantation. Blood 100(11):479b (Abstr.)
90. Mangel J, Leitch HA, Connors JM, et al. 2002. Intensive chemotherapy and autologous stem cell transplantation plus rituximab is superior to conventional chemotherapy for newly diagnosed advanced stage mantle cell lymphoma: a matched pair analysis. Blood 100(11): 780a (Abstr.)
91. Mangel J, Buckstein R, Imrie K, et al. 2002. Immunotherapy with rituximab following high-dose therapy and autologous stem-cell transplantation for mantle cell lymphoma. Semin. Oncol. 29:56-69
92. Brugger W. 2002. Improving outcomes in transplantation. Semin. Oncol. 29:23-26
93. Brugger W, Hirsch J, Repp R, et al. 2002. Treatment of follicular and mantle cell lymphoma with rituximab after high-dose chemotherapy and autologous blood stem cell transplantation: a multicenter phase II study. Blood 100(11):644a (Abstr.)
94. Buckstein RJ, Mangel J, Imrie K, et al. 2002. High dose therapy/ASCT consolidated with rituximab and or alpha interferon immunotherapy for relapsed follicular lymphoma prolongs progression free survival and achieves durable molecular remissions. Blood 100(11):647a-48a (Abstr.)
95. Geisler CH, Pedersen LB, Andersen NS, et al. 2002. Mantle cell lymphoma (MCL): increased clinical and molecular response rates adding Ara-C and rituximab to CHOP + BEAM and autologous stem cell transplantation. Results of the 1st and 2nd Nordic MCL Protocols. Blood 100(11):644a (Abstr.)
96. Khouri IF, Saliba RM, Hosing C, et al. 2002. Concurrent administration of high-dose rituximab (HD-R) with G/GM-CSF and autologous stem cell transplantation (ASCT) for relapsed B-cell lymphomas: increased efficacy without added toxicity. Blood 100(1):645a (Abstr.)
97. Khouri IF, Saliba RM, Giralt SA, et al. 2001. Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality. Blood 98:3595-99
98. Winter JN, Inwards D, Erwin W, et al. 2002. Zevalin dose-escalation followed by high-dose BEAM and autologous peripheral blood progenitor cell (PBPC) transplant in non-Hodgkin's lymphoma: early outcome results. Blood 100(11): 411a-12a (Abstr.)
99. Nademanee A, Molina A, Forman SJ, et al. 2002. A phase I/II trial of high-dose radioimmunotherapy (RIT) with Zevalin in combination with high-dose etoposide (VP-16) and cyclophosphamide (CY) followed by autologous stem cell transplant (ASCT) in patients with poor-risk or relapsed B-cell non-Hodgkin's lymphoma (NHL). Blood 100(11):182a (Abstr.)
100. Horwitz SM, Breslin S, Negrin RS, et al. 2000. Adjuvant rituximab after autologous peripheral blood stem cell transplant (APBSCT) results in delayed immune reconstitution without increase in infectious complications. Blood 96(11):384a (Abstr.)
101. White CA, Weaver RL, Grillo-Lopez AJ. 2001. Antibody targeted immunotherapy for treatment of malignancy. Annu. Rev. Med. 52:125-45
102. Witzig TE, Gordon LI, Cabanillas F, et al. 2002. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J. Clin. Oncol. 20:2453-63
103. Wiseman GA, Gordon L, Multani PS, et al. 2002. Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin's lymphoma and mild thrombocytopenia: a phase II multicenter trial. Blood 99:4336-42
104. Witzig TE, Flinn IW, Gordon LI, et al. 2002. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. J. Clin. Oncol. 20: 3262-69
105. Davis TA, Maloney DG, Grillo-Lopez AJ, et al. 2000. Combination immunotherapy of relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma with rituximab and interferon-alpha-2a. Clin. Cancer Res. 6:2644-52
106. Sacchi S, Federico M, Vitolo U, et al. 2001. Clinical activity and safety of combination immunotherapy with IFN-alpha 2a and rituximab in patients with relapsed low grade non-Hodgkin's lymphoma. Haematologica 86:951-58
107. Friedberg JW, Neuberg D, Gribben JG, et al. 2002. Combination immunotherapy with rituximab and interleukin 2 in patients with relapsed or refractory follicular non-Hodgkin's lymphoma. Br. J. Haematol. 117:828-34
108. Ansell SM, Witzig TE, Kurtin PJ, et al. 2002. Phase 1 study of interleukin-12 in combination with rituximab in patients with B-cell non-Hodgkin lymphoma. Blood 99:67-74
109. Faderl S, Thomas DA, O'Brien S, et al. 2002. Combined use of alemtuzumab and rituximab in patients with relapsed and refractory chronic lymphoid malignancies-an update of the M.D. Anderson experience. Blood 100(11):206a (Abstr.)
110. Hegde U, White T, Stetler-Stevenson M, et al. 2002. Phase I study of combination rituximab (CD20) and apolizumab (Hu1D10) monoclonal antibody therapy in previously treated B-cell lymphoma and chronic lymphocytic leukemia. Blood 100(11):358a (Abstr.)
111. Wilson WH, Neelapu S, White T, et al. 2002. Idiotype vaccine following EPOCH-rituximab treatment in untreated mantle cell lymphoma. Blood 100(11):162a (Abstr.)
112. 2002. Package insert. Zevalin® (ibritumomab tiuxetan), IDEC Pharmaceuticals Corporation, San Diego, CA
113. Witzig TE, White CA, Gordon LI, et al. 2002. Updated results of a randomized controlled study of Zevalin radioimmunotherapy (RIT) vs rituximab in B-cell non-Hodgkin's lymphoma (NHL). Ann. Oncol 13(Suppl. 2):38 (Abstr.)
114. Witzig TE, White CA, Wiseman GA, et al. 1999. Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20+ B-cell non-Hodgkin's lymphoma. J. Clin. Oncol. 17:3793-803
115. Osterborg A, Dyer MJ, Bunjes D, et al. 1997. Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H treatment in chronic lymphocytic leukemia. J. Clin. Oncol. 15:1567-74
116. Czuczman M, Witzig TE, Younes A, et al. 2002. IDEC-114, an anti-CD80 monoclonal antibody for relapsed or refractory, follicular NHL: phase I/II study of safety, efficacy, and pharmacokinetics. Blood 100(11):163a (Abstr.)
117. Haslett PA, Corral LG, Albert M, et al. 1998. Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset. J. Exp. Med. 187:1885-92
118. D'Amato RJ, Loughnan MS, Flynn E, et al. 1994. Thalidomide is an inhibitor of angiogenesis. Proc. Natl. Acad. Sci. USA 91:4082-85
119. Singhal S, Mehta J, Desikan R, et al. 1999. Antitumor activity of thalidomide in refractory multiple myeloma. N. Engl. J. Med. 341:1565-71
120. Dimopoulos MA, Zomas A, Viniou NA, et al. 2001. Treatment of Waldenstrom's macroglobulinemia with thalidomide. J. Clin. Oncol. 19:3596-601
121. Drach J, Kaufman H, Puespoek A, et al. 2002. Marked anti-tumor activity of rituximab plus thalidomide in patients with relapsed/resistant mantle cell lymphoma. Blood 100(11):162a (Abstr.)
122. Zecca M, Nobili B, Ramenghi U, et al. 2002. Rituximab for the treatment of refractory autoimmune hemolytic anemia in children. Blood 100(11):444a-45a (Abstr.)
123. Zecca M, De Stefano P, Nobili B, et al. 2001. Anti-CD20 monoclonal antibody for the treatment of severe, immune-mediated, pure red cell aplasia and hemolytic anemia. Blood 97:3995-97
124. Cooper N, Stasi R, Feuerstein M, et al. 2002. Transient B cell depletion with rituximab, an anti CD20 monoclonal antibody, resulted in lasting complete responses in 16 of 57 adults with refractory immune thrombocytopenic purpura. Blood 100(11):52a (Abstr.)
125. Cooper D, Feuerstein M, McFarland J, et al. 2002. Investigating the mechanism of action of rituximab, an anti-CD20 monoclonal antibody in adults with immune thrombocytopenic purpura. Blood 100(11):479a (Abstr.)
126. Stasi R, Pagano A, Stipa E, et al. 2001. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura. Blood 98:952-57
127. Tsai H-M, Gutterman LA, Kloster B, et al. 2002. Long-term remission of refractory thrombotic thrombocytopenic purpura after rituximab therapy. Blood 100(11):684a (Abstr.)
128. Ahmad A, Aggarwal A, Sharma D, et al. 2002. Rituximab for the treatment of relapsing/refractory thrombotic thrombocytopenic purpura (TTP). Blood 100(11):686a (Abstr.)
129. Leandro MJ, Edwards JC, Cambridge G, et al. 2002. An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum. 46:2673-77
130. Anolik JH, Campbell D, Felgar R, et al. 2002. B lymphocyte depletion in the treatment of systemic lupus (SLE): phase I/II trial of rituximab (Rituxan®) in SLE. Arthritis Rheum. 46(9 Suppl.):S289 (Abstr.)
131. Levine TD. 2002. A pilot study of rituximab therapy for refractory dermatomyositis. Arthritis Rheum. 46(9 Suppl.):S488 (Abstr.)
132. Specks U, Fervenza FC, McDonald TJ, et al. 2001. Response of Wegener's granulomatosis to anti-CD20 chimeric monoclonal antibody therapy. Arthritis Rheum. 44:2836-40
133. Cohen Y, Polliack A, Zelig O, et al. 2001. Monotherapy with rituximab induces rapid remission of recurrent cold agglutinin-mediated hemolytic anemia in a patient with indolent lymphoplasmacytic lymphoma. Leuk. Lymphoma 42:1405-8
134. Berentsen S, Tjonnfjord GE, Brudevold R, et al. 2001. Favourable response to therapy with the anti-CD20 monoclonal antibody rituximab in primary chronic cold agglutinin disease. Br. J. Haematol. 115:79-83
135. Hegde UP, Wilson WH, White T, et al. 2002. Rituximab treatment of refractory fludarabine-associated immune thrombocytopenia in chronic lymphocytic leukemia. Blood 100:2260-62
136. Wiestner A, Cho HJ, Asch AS, et al. 2002. Rituximab in the treatment of acquired factor VIII inhibitors. Blood 100:3426-28
137. Ratanatharathorn V, Carson E, Reynolds C, et al. 2000. Anti-CD20 chimeric monoclonal antibody treatment of refractory immune-mediated thrombocytopenia in a patient with chronic graft-versus-host disease. Ann. Intern. Med. 133:275-79
138. Arzoo K, Sadeghi S, Liebman HA. 2002. Treatment of refractory antibody mediated autoimmune disorders with an anti-CD20 monoclonal antibody (rituximab). Ann. Rheum. Dis. 61:922-24
139. Arnett FC, Edworthy SM, Bloch DA, et al. 1988. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 31:315-24
140. De Vita S, Zaja F, Sacco S, et al. 2002. Efficacy of selective B cell blockade in the treatment of rheumatoid arthritis: evidence for a pathogenetic role of B cells. Arthritis Rheum. 46:2029-33
141. Edwards JCW, Szczepanski L, Filipowicz-Sosnowka A, et al. 2002. Efficacy and safety of rituximab, a B-cell targeted chimeric monoclonal antibody: a randomized, placebo-controlled trial in patients with rheumatoid arthritis. Arthritis Rheum. 46(9 Suppl.):S197 (Abstr.)
142. Czuczman MS, Grillo-Lopez AJ, White CA, et al. 1999. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J. Clin. Oncol. 17:268-76
143. Czuczman M. 2001. Progression free survival (PFS) after six years (median) follow-up of the first clinical trial of rituximab/CHOP chemoimmunotherapy. Blood 98(11):601a (Abstr.)
144. McLaughlin P, Hagemeister FB, Rodriguez MA, et al. 2000. Safety of fludarabine, mitoxantrone, and dexamethasone combined with rituximab in the treatment of stage IV indolent lymphoma. Semin. Oncol. 27:37-41